Last reviewed · How we verify
Zoster Vaccine Recombinant, Adjuvanted
Zoster Vaccine Recombinant, Adjuvanted is a Recombinant subunit vaccine with adjuvant Biologic drug developed by Wuhan BravoVax Co., Ltd.. It is currently FDA-approved for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults. Also known as: Shingrix, SHINGRIX.
This recombinant zoster vaccine with adjuvant stimulates the immune system to generate protective antibodies and cell-mediated immunity against varicella-zoster virus (VZV) to prevent herpes zoster (shingles).
This recombinant zoster vaccine with adjuvant stimulates the immune system to generate protective antibodies and cell-mediated immunity against varicella-zoster virus (VZV) to prevent herpes zoster (shingles). Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults.
At a glance
| Generic name | Zoster Vaccine Recombinant, Adjuvanted |
|---|---|
| Also known as | Shingrix, SHINGRIX |
| Sponsor | Wuhan BravoVax Co., Ltd. |
| Drug class | Recombinant subunit vaccine with adjuvant |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant VZV glycoprotein E (gE) combined with an adjuvant system (AS01B) that enhances immune response. The adjuvant potentiates both humoral and cellular immunity, providing durable protection against reactivation of latent VZV infection that causes herpes zoster in older adults and immunocompromised individuals.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster in immunocompromised adults
Common side effects
- Injection site erythema
- Injection site pain
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older (PHASE2)
- Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older (PHASE1)
- Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (NA)
- A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years (PHASE1)
- Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoster Vaccine Recombinant, Adjuvanted CI brief — competitive landscape report
- Zoster Vaccine Recombinant, Adjuvanted updates RSS · CI watch RSS
- Wuhan BravoVax Co., Ltd. portfolio CI
Frequently asked questions about Zoster Vaccine Recombinant, Adjuvanted
What is Zoster Vaccine Recombinant, Adjuvanted?
How does Zoster Vaccine Recombinant, Adjuvanted work?
What is Zoster Vaccine Recombinant, Adjuvanted used for?
Who makes Zoster Vaccine Recombinant, Adjuvanted?
Is Zoster Vaccine Recombinant, Adjuvanted also known as anything else?
What drug class is Zoster Vaccine Recombinant, Adjuvanted in?
What development phase is Zoster Vaccine Recombinant, Adjuvanted in?
What are the side effects of Zoster Vaccine Recombinant, Adjuvanted?
What does Zoster Vaccine Recombinant, Adjuvanted target?
Related
- Drug class: All Recombinant subunit vaccine with adjuvant drugs
- Target: All drugs targeting Varicella-zoster virus glycoprotein E (gE)
- Manufacturer: Wuhan BravoVax Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Indication: Drugs for Prevention of herpes zoster in immunocompromised adults
- Also known as: Shingrix, SHINGRIX
- Compare: Zoster Vaccine Recombinant, Adjuvanted vs similar drugs
- Pricing: Zoster Vaccine Recombinant, Adjuvanted cost, discount & access